Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency
Status:
Terminated
Trial end date:
2018-06-04
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, single-dose study of the safety, tolerability, and
pharmacokinetics of Minocin® (minocycline) for injection in subjects with renal
insufficiency.
Phase:
Phase 1
Details
Lead Sponsor:
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Collaborators:
Innovative Medicines Initiative The Medicines Company Universitätsklinikum Köln